Key Facts

Dual diagnosis is the rule rather than the exception in both mental health and substance misuse services. The interaction between mental illness and substance use creates a cycle of mutual reinforcement that is challenging to treat. Integrated care models addressing both conditions simultaneously are recommended but inconsistently implemented.

Epidemiology

• General population: ~30% of people with any mental disorder have a co-morbid substance use disorder
• Severe mental illness (SMI): substance misuse prevalence:
  • Schizophrenia: ~40-50% lifetime substance use disorder
  • Bipolar disorder: ~40-60% lifetime substance use disorder
  • Personality disorder (especially EUPD/BPD): ~50-70%
• Substance misuse populations: psychiatric co-morbidity:
  • Depression: ~30-40%
  • Anxiety disorders: ~25-30%
  • PTSD: ~20-35%
  • Psychotic disorders: ~10-15%
  • ADHD: ~20-25% (often undiagnosed)
• Homeless population: rates of dual diagnosis up to ~70-80%
• Criminal justice: very high rates; dual diagnosis common among prison population

Aetiology

• Self-medication hypothesis: individuals use substances to alleviate psychiatric symptoms (e.g. alcohol for anxiety, cannabis for negative symptoms of schizophrenia)
• Shared vulnerability: common genetic, neurobiological, and environmental risk factors (e.g. dopamine system dysregulation, childhood adversity, social deprivation)
• Substance-induced mental illness: alcohol-related depression, cannabis-induced psychosis, stimulant-induced psychosis, drug-related anxiety disorders
• Mental illness predisposing to substance use: impulsivity, risk-taking, social marginalisation, cognitive deficits, peer group exposure
• Adverse childhood experiences (ACEs): childhood trauma is a common antecedent to both mental illness and substance misuse

Pathophysiology

• Dopamine dysregulation: central to both psychotic disorders and addiction; substance use further disrupts dopaminergic circuits
• HPA axis: chronic stress (from both mental illness and substance use) leads to dysregulated cortisol response
• Neuroinflammation: both chronic substance use and severe mental illness are associated with neuroinflammatory processes
• Structural brain changes: comorbid substance use accelerates grey matter loss in schizophrenia and bipolar disorder
• Pharmacokinetic interactions: substance use affects metabolism of psychotropic medications (e.g. smoking induces CYP1A2 → increased clozapine metabolism)

Common Dual Diagnosis Presentations

Psychosis and Substance Use

• Cannabis-associated first-episode psychosis: paranoid delusions, auditory hallucinations
• Stimulant-induced psychosis: persecutory delusions, tactile hallucinations (formication)
• Alcohol hallucinosis: auditory hallucinations with clear sensorium
• Chronic schizophrenia with co-morbid alcohol, cannabis, or polydrug use

Depression and Substance Use

• Alcohol-related depression: low mood, anhedonia, sleep disturbance worsened by alcohol
• Depression during opioid withdrawal or stimulant crash
• Persistent depression in chronic substance users
• Suicidal ideation commonly exacerbated by intoxication

Anxiety and Substance Use

• Alcohol use as anxiolytic → dependence → anxiety worsened by withdrawal cycle
• Benzodiazepine dependence in anxiety disorders
• Cannabis-related panic attacks and generalised anxiety
• PTSD with substance use as avoidance strategy

Personality Disorder and Substance Use

• Emotionally unstable personality disorder (EUPD/BPD): impulsive substance use, self-harm under intoxication
• Antisocial personality disorder: overlaps with addiction behaviours, criminal justice involvement
• Substance use to manage emotional dysregulation

Red Flags

• Suicidal ideation with substance use: very high risk — intoxication disinhibits and increases lethality
• Psychosis with continued substance use: risk of violence, self-neglect, treatment non-adherence
• Rapid deterioration in mental state: may indicate escalation of substance use or new substance
• Non-concordance with medication: substance use commonly leads to medication non-adherence
• Safeguarding concerns: children of parents with dual diagnosis; vulnerable adults; domestic abuse
• Homelessness: severely impacts ability to engage with treatment; increases all risks

Bedside

• Comprehensive substance use history: all substances, routes, frequency, duration, consequences
• Mental state examination: full MSE including cognitive assessment
• Risk assessment: suicide, self-harm, violence, vulnerability, safeguarding
• Urine drug screen: confirm substances used; identify unknown substances
• Screening tools:
  • AUDIT / AUDIT-C (alcohol)
  • DAST-10 (Drug Abuse Screening Test)
  • PHQ-9 (depression), GAD-7 (anxiety)
  • PCL-5 (PTSD)
  • Conners / DIVA (ADHD — if suspected)
• Collateral history: essential for accurate assessment; family, carers, GP records

Bloods

• FBC, LFTs, U&Es: substance-related organ damage
• TFTs: exclude thyroid disease contributing to mood symptoms
• Blood-borne virus screen: hepatitis B, C, HIV
• Prolactin: if on antipsychotics (also elevated in some substance use)
• HbA1c and lipids: metabolic monitoring on antipsychotics
• Clozapine level: if on clozapine — smoking cessation significantly increases levels (CYP1A2 effect)

Imaging

• MRI brain: if first-episode psychosis, atypical presentation, or organic cause suspected
• CT head: acute presentations with altered consciousness, head injury

Special Tests

• Neuropsychological testing: if persistent cognitive impairment after period of abstinence
• ECG: QTc monitoring if on methadone or antipsychotics
• Structured clinical interview: e.g. SCID or MINI for formal diagnostic assessment
• Capacity assessment: under Mental Capacity Act 2005 — frequently required in dual diagnosis

Non-pharmacological

• Integrated treatment model: addressing substance use and mental health simultaneously within one team or through close collaboration
  • NICE CG120: recommends mental health services take the lead for people with severe mental illness and substance misuse
  • "No wrong door": neither service should refuse to treat based on the other condition
• Care coordination: CPA (Care Programme Approach) for those with SMI; key worker / care coordinator
• Psychosocial interventions:
  • CBT: adapted for dual diagnosis; addresses both substance use triggers and psychiatric symptoms
  • Motivational interviewing: addresses ambivalence about substance use change
  • Contingency management: incentive-based approaches for substance reduction
  • Family interventions: psychoeducation, carer support (particularly in psychosis)
• Trauma-informed care: recognising the high prevalence of trauma; avoiding re-traumatisation
• Housing and social support: housing-first approaches; benefits advice; social inclusion programmes
• Peer support: recovery workers with lived experience

Pharmacological

• Principles:

  • Treat both conditions — do not withhold psychiatric medication because of substance use
  • Choose medications with lower interaction potential and abuse liability
  • Monitor adherence closely; consider depot/long-acting formulations for psychosis
  • Be cautious with benzodiazepines (dependence risk, respiratory depression with opioids)

• Psychosis + substance use:

  • Antipsychotics: second-generation preferred; aripiprazole may have lower metabolic side-effect burden
  • Clozapine: evidence for reducing substance use in treatment-resistant schizophrenia; monitor carefully — smoking cessation/reduction significantly increases clozapine levels (CYP1A2 induction by smoking)
  • Depot antipsychotics: e.g. paliperidone palmitate, aripiprazole long-acting injection — improves adherence

• Depression + substance use:

  • Reassess mood after 2-4 weeks of abstinence — substance-induced depression often improves
  • If depression persists: SSRIs first-line (e.g. sertraline 50-200 mg OD; fluoxetine 20-60 mg OD)
  • Avoid TCAs: risk of toxicity in overdose; lower seizure threshold
  • Mirtazapine 15-45 mg ON: useful for insomnia and appetite stimulation; low seizure risk

• Anxiety + substance use:

  • SSRIs first-line for GAD, panic, social anxiety
  • Avoid benzodiazepines: high abuse potential, cross-tolerance with alcohol, respiratory depression risk with opioids
  • Pregabalin 150-600 mg/day: licensed for GAD but has abuse potential — prescribe cautiously in substance misusers
  • Propranolol 40 mg BD-TDS: for somatic anxiety symptoms without abuse potential

• ADHD + substance use:

  • Treat ADHD — untreated ADHD is a risk factor for substance misuse
  • Lisdexamfetamine (Elvanse): preferred stimulant — pro-drug with lower abuse potential
  • Atomoxetine 40-100 mg OD: non-stimulant alternative; no abuse potential
  • Stabilise substance use before or concurrently with ADHD treatment initiation

• Substance-specific treatment: OST for opioid dependence, managed withdrawal for alcohol, NRT/varenicline for smoking — should proceed alongside psychiatric treatment

Surgical

• Not applicable

Referral Criteria

• Community mental health team (CMHT): severe mental illness with substance misuse
• Early Intervention in Psychosis (EIP): first-episode psychosis with substance use
• Community drug and alcohol services: for substance-specific treatment alongside mental health care
• Crisis team / home treatment team: acute psychiatric crisis with substance involvement
• Inpatient psychiatric admission: acute psychosis, high suicide risk, severe self-neglect, failed community management
• Specialist dual diagnosis team: where available — provides integrated assessment and care

Outcomes

• Poorer outcomes than either condition alone: dual diagnosis associated with increased hospitalisation, homelessness, violence, victimisation, and mortality
• Suicide risk: substance misuse present in ~25-35% of completed suicides; risk is multiplicative when combined with depression or psychosis
• Treatment engagement: often lower than for single diagnosis; frequent loss to follow-up
• Integrated treatment: produces better outcomes than parallel or sequential treatment for engagement, substance use reduction, and psychiatric symptom improvement
• Recovery is possible: with sustained integrated support, many individuals achieve stability and improved quality of life

Complications

• Increased relapse of both conditions: substance use precipitates psychiatric relapse and vice versa
• Medication non-adherence: major contributor to psychiatric relapse; substance use disrupts routines and insight
• Physical health: dual diagnosis associated with worse physical health outcomes; cardiovascular disease, infections, liver disease
• Homelessness: both a cause and consequence of dual diagnosis; dramatically worsens prognosis
• Criminal justice involvement: higher rates of offending and incarceration
• Social exclusion: stigma from both mental illness and substance misuse; reduced employment, relationship breakdown
• Premature mortality: life expectancy reduced by 15-20 years compared to general population in people with SMI and substance misuse

Models of Care for Dual Diagnosis

Substance Use and Specific Psychiatric Conditions

Key Policy and Guidance